Valuation: MedinCell S.A.

Capitalization 98Cr 114.24Cr 90Cr 86Cr 157.22Cr 11TCr 159.81Cr 1.08TCr 417.28Cr 5.2TCr 428.73Cr 419.54Cr 18TCr P/E ratio 2026 *
-55.8x
P/E ratio 2027 * 525x
Enterprise value 96Cr 112.09Cr 88Cr 84Cr 154.25Cr 11TCr 156.8Cr 1.06TCr 409.42Cr 5.11TCr 420.65Cr 411.64Cr 18TCr EV / Sales 2026 *
31.6x
EV / Sales 2027 * 21.8x
Free-Float
61.66%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MedinCell S.A.

1 day-4.67%
1 week+3.95%
Current month+10.94%
1 month+9.00%
3 months+9.43%
6 months-10.05%
Current year+8.65%
1 week 26.32
Extreme 26.32
29.1
1 month 22.52
Extreme 22.52
29.1
Current year 19.69
Extreme 19.69
29.3
1 year 14.93
Extreme 14.93
39.68
3 years 5.25
Extreme 5.25
39.68
5 years 4.73
Extreme 4.73
39.68
10 years 4.35
Extreme 4.35
39.68
Manager TitleAgeSince
Chief Executive Officer 62 09/01/2003
Director of Finance/CFO 52 01/09/2023
Chief Tech/Sci/R&D Officer 67 09/05/2022
Director TitleAgeSince
Director/Board Member 62 09/01/2003
Chairman - 13/03/2024
Director/Board Member - 25/05/2016
Change 5d. change 1-year change 3-years change Capi.($)
-4.67%+3.95%+76.99%+288.37% 120.36Cr
-0.00%+5.95%+37.04%+131.28% 90TCr
-1.77%+2.44%+51.53%+42.09% 56TCr
-0.18%+4.39%+15.80%+43.52% 37TCr
+0.91%+0.53%+25.74%+12.38% 33TCr
-0.79%+2.39%+36.02%+13.51% 29TCr
-0.10%+2.98%+30.60%+26.10% 28TCr
-1.79%0.00%+48.90%-4.29% 28TCr
+0.91%+1.25%-30.88%-49.10% 21TCr
-2.22%-1.62%+20.10%+39.73% 18TCr
Average -0.90%+2.89%+31.19%+54.36% 33.94TCr
Weighted average by Cap. -0.45%+2.46%+31.31%+49.79%

Financials

2026 *2027 *
Net sales 3.05Cr 3.55Cr 2.79Cr 2.66Cr 4.88Cr 340.3Cr 4.96Cr 33Cr 13Cr 161.54Cr 13Cr 13Cr 562.81Cr 4.41Cr 5.13Cr 4.03Cr 3.85Cr 7.05Cr 491.83Cr 7.17Cr 48Cr 19Cr 233.48Cr 19Cr 19Cr 813.43Cr
Net income -1.57Cr -1.82Cr -1.43Cr -1.37Cr -2.51Cr -174.87Cr -2.55Cr -17Cr -6.66Cr -83Cr -6.84Cr -6.69Cr -289.22Cr 50.31L 58.46L 46L 43.89L 80.45L 56Cr 81.78L 5.52Cr 2.14Cr 27Cr 2.19Cr 2.15Cr 93Cr
Net Debt -1.85Cr -2.15Cr -1.69Cr -1.62Cr -2.96Cr -206.45Cr -3.01Cr -20Cr -7.86Cr -98Cr -8.08Cr -7.9Cr -341.44Cr -2.25Cr -2.62Cr -2.06Cr -1.97Cr -3.61Cr -251.41Cr -3.67Cr -25Cr -9.57Cr -119.35Cr -9.83Cr -9.62Cr -415.8Cr
Logo MedinCell S.A.
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2025, the company had a portfolio of 2 products in phase III clinical development and 3 products in preclinical development.
Employees
145
Date Price Change Volume
15/26/15 27.38 -4.67% 90,102
14/26/14 28.72 +2.28% 80,764
13/26/13 28.08 +1.81% 1,67,752
12/26/12 27.58 +1.92% 1,26,079
11/26/11 27.06 +3.20% 1,10,827
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
27.38EUR
Average target price
34.44EUR
Spread / Average Target
+25.77%

Quarterly revenue - Rate of surprise